Chinese Regulators Approve Genesis Medtech’s iReach Omnia

Genesis Medtech’s iReach Omnia, billed as the world’s first powered stapler with 90-degree articulation capability, has been approved by China’s National Medical Products Administration (NMPA). The innovation addresses key challenges in complex laparoscopic surgeries by giving surgeons better precision and access in tight and deep anatomical positions.

Surgical staplers play a critical role in minimally invasive surgeries by replacing traditional manual sutures, offering more consistent clinical outcomes while reducing infection risk and enhancing surgical efficiency. However, existing staplers, with typical articulation angles from 45 degrees to 60 degrees, face challenges in complex procedures such as low anterior resection or single-port thoracic surgery, where restricted anatomical access in the pelvis or chest cavity demands greater flexibility.

The iReach Omnia sets a new standard in surgical stapling with its 90-degree articulation capability, giving surgeons the necessary maneuverability and precision to perform effective stapling in confined spaces. The advancement potentially reduces the need for multiple stapler firings and minimizes weak points in the staple line, thus lowering the risk of anastomotic leakage. By addressing these critical issues, the iReach Omnia empowers surgeons to deliver better patient outcomes in complex procedures such as colorectal and thoracic surgeries, according to the company.

Colorectal cancer is one of the top three cancers worldwide, affecting millions of people annually.¹ Surgical tumor resection remains the primary treatment for low rectal cancer but surgeons face significant challenges in completely removing the tumor, achieving clear margins in confined spaces, preserving sphincter function, and minimizing complications such as anastomotic leakage.² The iReach Omnia’s 90-degree articulation capability addresses these challenges by enabling precise vertical cutting and stapling in the low rectal resections, reducing the risk of leakage and ultimately, enhancing long-term patient outcomes.

Genesis MedTech Group is a medical device company headquartered in Singapore. Founded by a group of professionals and entrepreneurs with medtech experience globally, the company’s product portfolio focuses on multi-therapy medical device products for emerging markets with sales and distribution through its established commercial network. Genesis MedTech Group covers the entire industry value chain of research and development, production, quality management, supply chain, marketing, and sales.

References
¹ World Health Organization. (2020). Colorectal cancer. Retrieved from https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
² Tsalikidis, C., Mitsala, A., Mentonis, V. I., Romanidis, K., Pappas-Gogos, G., Tsaroucha, A. K., & Pitiakoudis, M. (2023). Predictive Factors for Anastomotic Leakage Following Colorectal Cancer Surgery: Where Are We and Where Are We Going? Current Oncology, 30(3), 3111-3137. https://doi.org/10.3390/curroncol30030236